Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21363538 | 0.80 | TRPA1 (0.37) | LMNATRPA1 | |
| SCHEMBL122153 | 0.77 | POLB (0.51) | KDM4EMEN1KMT2A | |
| SCHEMBL12410751 | 0.77 | LTA4H (0.35) | LMNAKDM4EMEN1KMT2A | |
| SCHEMBL10328327 | 0.77 | ACVR1 (0.51) | IDO1FEN1TRPA1BRD4PDE4A | |
| SCHEMBL21363499 | 0.76 | ALDH1A1 (0.37) | LMNATRPA1KDM4EKMT2A | |
| SCHEMBL21363469 | 0.76 | TRPA1 (0.32) | LMNATRPA1 | |
| SCHEMBL9910063 | 0.75 | MAPT (0.44) | FEN1LMNANPSR1KDM4EMEN1 | |
| SCHEMBL26155651 | 0.75 | KDM4E (0.54) | FEN1KDM4EKMT2APDE4APDE4B | |
| SCHEMBL14867109 | 0.75 | ACVR1 (0.35) | LMNANPSR1MEN1KMT2A | |
| SCHEMBL26155649 | 0.75 | TRPA1 (0.35) | LMNATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711004-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | IDO1 585/4885FEN1 4672/4885LMNA 4575/4885 |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | IDO1 823/4885FEN1 4389/4885LMNA 3217/4885 |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | IDO1 759/4885FEN1 4523/4885LMNA 3183/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | IDO1 759/4885FEN1 4523/4885LMNA 3183/4885 |
| US-20230121700-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | IDO1 759/4885FEN1 4523/4885LMNA 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.